HER2: From Classic Oncogene to Precision Subtyping of Two Pathogenic Mechanisms

Author: Senior Product Manager of UA Views：5

This article focuses on the molecular characteristics and clinical pathogenic mechanisms of human epidermal growth factor receptor 2 (HER2), systematically elaborating on its receptor properties as a HER family member that has no known ligand and relies on dimerization for activation, analyzing the differences between two types of pathogenic mechanisms—protein overexpression caused by HER2 gene amplification and HER2 mutations (including exon 20 insertion mutations)—in terms of cancer type distribution and molecular consequences, and exploring the logic of targeted therapeutic strategies based on mechanism-based classification.

Recent Advances
Product Information

Recent Advances

HER2: From a Classic Oncogene to Precision Classification of Two Pathogenic Mechanisms

Brief Introduction: This article focuses on the molecular characteristics and clinical pathogenic mechanisms of human epidermal growth factor receptor 2 (HER2), systematically elaborating on its receptor properties as a HER family member with no known ligand that relies on dimerization for activation, analyzing the differences between the two pathogenic mechanisms—HER2 gene amplification-induced protein overexpression and HER2 mutations (including exon 20 insertion mutations)—in terms of cancer type distribution and molecular consequences, and discussing the logic of targeted therapeutic strategies based on mechanism-based classification.

I. The Discovery History and Family Positioning of HER2.

HER2 is an oncogene discovered relatively early, first identified in 1984. Over nearly 40 years, the mechanisms of action, drugs, and novel therapies targeting this target have been continuously discovered and innovated, achieving tremendous progress, and it remains a drug target with enormous potential. The HER protein family consists of four highly homologous protein members: EGFR (ERBB1/HER1), HER2 (ERBB2), HER3 (ERBB3), and HER4 (ERBB4), which control cell growth, survival, differentiation, and migration. The four members are highly homologous in structure but each has distinct characteristics in ligand dependency and kinase activity. This “homologous but not equivalent” family landscape determines that the functional positioning of HER2 must be understood within the family interaction network rather than viewed in isolation.

II. The Ligand-Independent Dimerization Activation Mechanism of HER2.

The extracellular domain of HER2 has no known ligand and is activated through the formation of homodimers or heterodimers. Dimerization leads to phosphorylation of tyrosine kinase residues in the cytoplasmic domain, thereby activating signaling pathways such as phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK), leading to cell cycle progression, cell differentiation, and proliferation. The key to this activation mode is that HER2 signal output does not depend on ligand binding events but rather on its dimerization state on the cell membrane. When HER2 density on the cell membrane increases due to gene amplification, the probability of dimerization increases accordingly, and signal output shifts from a controlled state to sustained activation. Therefore, HER2 overexpression or mutations are closely associated with the degree of malignancy in many epithelial cell cancers. In recent years, HER2 antibody drugs have achieved new breakthroughs in tumor therapy with advantages such as high specificity, efficacy, and safety.

III. The First Type of Pathogenic Mechanism: Gene Amplification-Induced Protein Overexpression.

Clinically, two main types of pathogenic mechanisms have been identified for HER2. The first is HER2 gene amplification-induced protein overexpression, which mainly occurs in approximately 20% to 25% of breast cancers (termed HER2-positive breast cancer) as well as in some gastric cancers, gastroesophageal junction cancers, biliary tract cancers, colorectal cancers, non-small cell lung cancers, and bladder cancers. From a molecular logic perspective, gene amplification causes HER2 protein to be abundantly expressed on the cell membrane surface; increased receptor density directly drives an increase in dimerization probability, thereby producing sustained signal output. The characteristic of this mechanism is that “quantitative changes in protein lead to qualitative changes in signaling”—the structure of individual receptor molecules is unchanged, but the increase in total membrane surface receptors alters the dimerization equilibrium. Therefore, detection for this mechanism centers on protein overexpression and gene amplification, and therapeutic strategies primarily rely on antibody-based drugs that bind to membrane surface receptors.

IV. The Second Type of Pathogenic Mechanism: HER2 Mutations and Exon 20 Insertions.

The second type is HER2 mutations, including HER2 point mutations and HER insertion mutations, among which HER2 exon 20 insertion mutations are particularly important. These are commonly found in non-small cell lung cancer, accounting for approximately 2.27%, with three insertion mutations—HER2 A775_G776insYVMA, G776delinsVC, and P780_Y781insGSP—being the most common. Unlike gene amplification, the molecular consequence of insertion mutations is a conformational change in the kinase domain that maintains the receptor in an activated state even in the absence of dimerization partners or ligand stimulation, with signal output independent of increased membrane surface receptor density. This mechanistic difference has direct clinical implications: antibody-based drugs targeting gene amplification primarily act on the cell membrane surface, whereas interventions targeting kinase domain mutations require small molecule inhibitors to enter cells and exert their effects. Therefore, the two types of pathogenic mechanisms are not only a distinction at the molecular level but also determine the choice of detection methods and therapeutic modalities.

V. The Logic of Detection and Treatment Strategies Based on Mechanism-Based Classification.

The coexistence of two types of pathogenic mechanisms requires that HER2-related diagnosis and treatment must be established on the basis of clear molecular classification. For the gene amplification type, detection primarily involves immunohistochemistry to assess protein expression levels and in situ hybridization to confirm gene copy number, with treatment centered on anti-HER2 monoclonal antibodies and antibody-drug conjugates. For the mutation type, detection relies on sequencing technologies to identify specific mutation types such as exon 20 insertions, with treatment primarily oriented toward small molecule tyrosine kinase inhibitors. This “mechanism—detection—drug” tripartite matching diagnostic and therapeutic logic is the core manifestation of HER2's evolution from a single target to precision classification over nearly four decades, and is also the foundation for its continuous expansion of indications across multiple solid tumors.

VI. Conclusion.

As a classic oncogene discovered in 1984, HER2 has become one of the most representative targets in the field of precision therapy for solid tumors, owing to its receptor properties as a HER family member with no known ligand that relies on homodimerization or heterodimerization for activation, its signaling mechanism driving cell cycle progression and proliferation through PI3K and MAPK pathways, and the clear classification of two pathogenic mechanisms: gene amplification-induced protein overexpression and HER2 mutations including exon 20 insertions.

VII. Frequently Asked Questions and Product Information for HER2 Binding Activity Detection

To facilitate researchers and drug development teams in searching for evaluation schemes and product information for HER2 interactions, this section addresses common questions about HER2 binding activity detection in a Q&A format and provides the product positioning and applicable scenarios of Her2/ErbB2 His Tag Protein, Mouse.

Q1: What methods are used to detect HER2 binding activity?
HER2 activation does not depend on known ligands but rather on its dimerization state on the cell membrane. Therefore, in vitro evaluation of HER2 typically focuses on the direct binding of targeted antibodies or small molecules to the HER2 extracellular domain or kinase domain. Currently, in vitro methods for evaluating such interactions mainly include enzyme-linked immunosorbent assay (ELISA), surface plasmon resonance (SPR) and bio-layer interferometry (BLI), as well as time-resolved fluorescence resonance energy transfer (TR-FRET). For the determination of binding affinity between antibodies and the HER2 extracellular domain, ELISA and SPR/BLI are commonly used methods that are easy to operate and highly reproducible.

Q2: How does ELISA evaluate the binding activity of anti-HER2 antibodies?
In a typical ELISA system, recombinant HER2 protein is coated onto microplate wells, gradient-diluted candidate antibodies are added and incubated, and absorbance signals are read through enzymatic secondary antibody color development. By plotting antibody concentration against signal values, the half-maximal effective concentration (EC50) can be fitted to compare the binding capacity of different antibodies to HER2. Since the HER2 protein carries a His tag, an anti-His antibody can also be used to capture HER2 followed by detection of candidate antibody binding, flexibly adapting to different experimental requirements. Additionally, in mouse tumor model evaluation, mouse-derived HER2 protein can be used to verify the species cross-reactivity of candidate drugs.

Q3: What is Her2/ErbB2 His Tag Protein, Mouse?
Her2/ErbB2 His Tag Protein, Mouse (Catalog No. UA010148) is a mouse-derived HER2 recombinant protein provided by UniOne (UA-Bio), expressed in the HEK293 expression system with a C-terminal His tag, facilitating efficient purification through immobilized metal affinity chromatography and enabling detection and capture via anti-His tag antibodies. This product is suitable for binding activity analysis of HER2 with targeted antibodies and small molecule inhibitors, in vitro studies of HER2 dimerization and kinase activation mechanisms, as well as efficacy evaluation and species cross-reactivity verification of HER2-targeted drugs in mouse tumor models.

Q4: What experimental scenarios is this product suitable for?
The main application scenarios of this product include: binding activity analysis and EC50 determination of HER2 with targeted antibodies; in vitro binding evaluation of HER2 with targeted small molecule inhibitors; in vitro studies of HER2 dimerization and kinase activation mechanisms; efficacy evaluation and species cross-reactivity verification of HER2-targeted drugs in mouse tumor models; establishment and validation of HER2 immunoassay methods; and parallel comparison of binding activity between different antibody or protein batches.

Q5: What are the advantages of His-tagged HER2 protein in experiments?
The His tag facilitates efficient purification through immobilized metal affinity chromatography, improving protein yield and purity; meanwhile, the His tag can serve as a capture or detection tag, enabling directional immobilization of HER2 onto ELISA plates or SPR chip surfaces via anti-His antibodies, flexibly adapting to various experimental modes such as “protein coating—antibody detection” or “antibody capture—protein detection.” For a receptor like HER2 whose activation prerequisite is dimerization, His-tagged protein provides a versatile and easy-to-operate reagent basis for antibody binding activity evaluation and species cross-reactivity studies.

Product Information at a Glance

Product Name	Her2/ErbB2 His Tag Protein, Mouse (Catalog No.: UA010148)
Brand	UniOne (UA-Bio)
Molecular Aliases	ERBB2, HER2, NEU, NGL, CD340, MLN19, HER-2/neu, c-erb B2
Accession	P70424
Expressed Sequence	Thr23-Thr1221, with C-terminal His Tag
Expression System	HEK293
Molecular Weight	130-150 kDa (Reducing)
Purity	>90% by SDS-PAGE under reducing conditions
Endotoxin Level	<0.1 EU/μg
Tag	His Tag
Form	Lyophilized Powder
Buffer System	PBS, pH7.4
Reconstitution Method	After quick centrifugation, reconstitute with ultrapure water to 0.1-1 mg/mL according to the specification
Storage Conditions	Lyophilized powder stored at -20 to -80°C, stable for 12 months from the date of receipt; after reconstitution, store at -20 to -80°C for 3 months or at 2 to 8°C for 1 week under sterile conditions; avoid repeated freeze-thaw cycles
Core Applications	Quantitative binding activity analysis, antibody and small molecule screening, species cross-reactivity verification, mechanism of action studies
Common Search Terms	HER2 binding activity detection, Her2/ErbB2 His Tag Protein, HER2 antibody screening, HER2 species cross-reactivity, HER2 recombinant protein, UA010148, UniOne

To conduct HER2 binding activity detection or species cross-reactivity evaluation of HER2-targeted drugs, search for the full product name “Her2/ErbB2 His Tag Protein, Mouse” or catalog number “UA010148” in the UniOne (UA-Bio) Product Center to obtain product manuals, experimental protocols, and supporting reagent information.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next